Clinical Trial Update: A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of Imatinib Mesylate in patients with Idiopathic Hypereosinophilic Syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypereosinophilic Syndrome | Phase 2 | Status: TERMINATED